Today, the official website of the Drug Evaluation Center (CDE) of the China State Drug Administration announced that Novo Nordisk (Novo Nordisk)'s new class 1 drug amycretin tablets has been accepted. According to public information, this is a long-term co-agonist for oral GLP-1 receptor and insulin receptor developed by Novo Nordisk, and is a next-generation weight loss therapy. In a small phase 1 clinical study recently announced by Novo Nordisk, patients lost 13.1% of their body weight after 12 weeks of treatment with this product (vs. 1.1% in the placebo group), showing rapid weight loss effects and good clinical application potential.
12周减重超13% 诺和诺德这款口服疗法在中国申报临床
Reduced weight by more than 13% in 12 weeks, Novo Nordisk's oral treatment declared clinical in China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.